# C_2016261EN.01000601.xml

| 19.7.2016 | EN | Official Journal of the European Union | C 261/6 |
| --- | --- | --- | --- |

19.7.2016

EN

Official Journal of the European Union

C 261/6

---

Prior notification of a concentration

(Case M.8061 — IMS Health/Quintiles)

(Text with EEA relevance)

(2016/C 261/06)

| 1. | On 7 July 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which IMS Health Holdings (‘IMS Health’, United States) enters into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation with Quintiles Transnational Holdings Inc. (‘Quintiles’, United States). |
| --- | --- |

1.

On 7 July 2016, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which IMS Health Holdings (‘IMS Health’, United States) enters into a full merger within the meaning of Article 3(1)(a) of the Merger Regulation with Quintiles Transnational Holdings Inc. (‘Quintiles’, United States).

1

| 2. | The business activities of the undertakings concerned are:
  —   IMS Health: a global information and technology services company providing healthcare companies with solutions to measure and improve their performance, such as pricing and market access, data management, prescribing trends, etc.,
  —   Quintiles: global provider of product development services and commercial outsourcing services to support healthcare companies develop and commercialize new therapies. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   IMS Health: a global information and technology services company providing healthcare companies with solutions to measure and improve their performance, such as pricing and market access, data management, prescribing trends, etc.,

IMS Health

—   Quintiles: global provider of product development services and commercial outsourcing services to support healthcare companies develop and commercialize new therapies.

Quintiles

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8061 — IMS Health/Quintiles, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference M.8061 — IMS Health/Quintiles, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---